Colon Cancer Clinical Trial
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Hepatic arterial infusion uses a catheter to carry tumor-killing substances directly into the liver. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving floxuridine and dexamethasone directly into the arteries around the tumor together with combination chemotherapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well hepatic arterial infusion with floxuridine and dexamethasone works when given together with combination chemotherapy in treating patients with colorectal cancer that has spread to the liver.
Assess the rate of conversion to complete resection in patients with initially unresectable colorectal cancer metastatic to the liver treated with hepatic arterial infusion comprising floxuridine and dexamethasone in combination with systemic irinotecan hydrochloride and either oxaliplatin or leucovorin calcium/fluorouracil.
Evaluate the time to progression in patients treated with this regimen.
Evaluate disease-free survival of patients treated with this regimen.
Evaluate overall survival of patients treated with this regimen.
Determine the response rate (complete, partial, and moderate response) in patients treated with this regimen.
Evaluate the safety profile and tolerability of this regimen in these patients.
Assess the expression pattern of the VEGF receptor VEGFR1, VEGFR2, and VEGFR3 and their cognate ligands (i.e., VEGF-A, VEGF-B, VEGF-C, VEGF-D, and P1GF) in patients treated with this regimen.
Correlate circulating angiogenic markers with tumor resectability, disease progression, and patient survival.
Procure normal and diseased liver tissue for evaluation of thymidylate synthase, p53 gene, p21, topoisomerase 1, dihydropyrimidine dehydrogenase, and excision repair cross-complementing gene levels.
Assess the expression pattern of tissue factor (TF) and explore its correlation with the TF receptors PAR-1, PAR-2, TF regulators PTEN, k-ras, b- raf, p53, and outcome.(Closed as of 11/30/10)
Assess the prognostic and predictive role of preoperative, pretreatment, and during treatment serum TF in regards to outcome (progression-free survival and overall survival) and response to treatment with this regimen and to salvage treatments such as EGFR-inhibitors.(Closed as of 11/30/10)
OUTLINE: This is an open-label, nonrandomized study. Patients are assigned to 1 of 2 treatment groups according to receipt of more than 2 prior courses of oxaliplatin (no vs yes).
Group 1 (no more than 2 prior courses of oxaliplatin): Patients receive hepatic arterial infusion (HAI) therapy comprising floxuridine and dexamethasone continuously on days 1-14. Patients also receive oxaliplatin IV over 2 hours and irinotecan hydrochloride IV over 30 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Group 2 (more than 2 prior courses of oxaliplatin): Patients receive HAI therapy as in group 1. Patients also receive irinotecan hydrochloride IV over 30 minutes and leucovorin calcium IV over 30 minutes on days 1 and 15 and fluorouracil IV continuously over 48 hours on days 1, 2, 15, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
In both groups, patients may undergo complete resection of liver metastases after completion of at least 3 courses of therapy.
Some patients undergo blood and tissue collection periodically for correlative and immunological studies. Samples are analyzed for VEGF receptor VEGFR1, VEGFR2, VEGFR3, thymidylate synthase, p53, p21, topoisomerase 1, dihydropyrimidine dehydrogenase, and excision repair cross-complementing gene levels.
After completion of study treatment, patients are followed every 3 months for 2 years, every 4 months for 3 years, and then annually thereafter.
Histologically confirmed colorectal adenocarcinoma metastatic to the liver
Previously treated or untreated disease
No clinical or radiographic evidence of extrahepatic disease
Primary tumor may be present at study registration provided it is not obstructing the intestinal lumen or is significantly bleeding
If present, the primary tumor will be resected at the time of pump placement
Must have inoperable liver metastases confirmed by 2-3 hepatobiliary surgeons and the assigned radiologist
Liver metastases < 70% of the liver parenchyma
Inoperable liver metastases is defined by one of the following:
More than 6 metastases in a single lobe with one lesion ≥ 5 cm
At least 6 metastases distributed diffusely in both lobes of the liver
When a margin-negative resection would require resection of all three hepatic veins, both portal veins, or the retrohepatic vena cava
Requires a resection that leaves < 2 hepatic segments (not including the caudate lobe) behind with adequate arterial or portal inflow, venous outflow, and biliary drainage
No ascites or hepatic encephalopathy
No history of primary CNS tumors
Karnofsky performance status 60-100%
WBC ≥ 3,000/mm^3
ANC ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3
INR < 1.5
Hemoglobin ≥ 9 g/dL
Creatinine ≤ 1.5 mg/dL
Total bilirubin ≤ 1.5 mg/dL
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Physically able to tolerate major partial hepatectomy
No active infection
No concurrent active malignancies, except potentially resectable primary colorectal tumor
No bleeding diathesis or coagulopathy
No history of serious systemic disease, including any of the following:
Myocardial infarction within the past 6 months
Uncontrolled hypertension (i.e., blood pressure > 150/100 mm Hg on medication)
New York Heart Association class II-IV congestive heart failure
Unstable symptomatic arrhythmia requiring medication
Chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) allowed
Peripheral vascular disease ≥ grade 2
No serious or nonhealing active wound, ulcer, or bone fracture
No history of seizures not well controlled with standard medical therapy
No stroke or transient ischemic attack within the past 6 months
No concurrent obstruction of the gastrointestinal or genitourinary tract
PRIOR CONCURRENT THERAPY:
At least 4 weeks since prior radiotherapy to the pelvis
Prior chemotherapy allowed
No prior radiotherapy, hepatic thermal ablation, or resection (other than biopsy) to the liver
No prior floxuridine
No prior hepatic arterial infusion
No concurrent chronic aspirin (> 325 mg/day) or nonsteroidal anti-inflammatory medications known to inhibit platelet function
No other concurrent investigational agents
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Basking Ridge New Jersey, , United States
Commack New York, 11725, United States
New York New York, 10065, United States
Rockville Centre New York, , United States
Sleepy Hollow New York, , United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.